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EFFECTS OF INTERMITTENT PNEUMATIC COMPRESSION ON DELAYED
ONSET MUSCLE SORENESS (DOMS) IN LONG DISTANCE RUNNERS
SHANE N. DRAPER
ABSTRACT
Purpose: The purpose was to measure the effects of intermittent pneumatic
compression (NormaTec, NT) on muscle inflammation after long distance running.
Methods: Ten long distance runners, five males and five females, ages 18-55 years
performed two, 20 mile runs at 70% VO2 max. The runs were followed by either no
treatment (control) or NT treatment for five consecutive days. For the NT run, subjects
were treated for one hour immediately following the run and daily for five days after. For
the control run, subjects did not receive any treatment. Serum C – reactive protein (CRP),
a marker of muscle inflammation, was measured pre and post run and daily thereafter for
five days for both trials. Repeated measures ANOVA and two-way ANOVA were used to
assess treatment differences. Results: The results indicated no significant difference (P >
0.05) between the control and treatment runs in CRP levels. There was also no gender
differences or order effect of runs. Subjective pain ratings indicated no significant
difference in pain between the control and treatment runs except when comparing the
first run compared to the second run (regardless of whether the first run was a treatment
or control run); there was a significant difference in which the subjects experienced less
pain on the second run. There was no significant difference in mean weight loss, fluid
intake, sweat rate, heart rate, percentage of maximum heart rate, or percentage of
maximum VO2 max. There was, however, a significant difference (P = 0.038) in running
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time when comparing the control run (196.2 minutes) against the treatment run (204.8
minutes). Conclusions: Although the test subjects recovered one day earlier when using
the NT device (Day 4) compared to the control (Day 5), this difference was not
significant.
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CHAPTER I
INTRODUCTION
Background
Delayed onset of muscle soreness (DOMS) is an effect of performing an exercise that
places a great deal of strain on the skeletal muscles, especially eccentric exercise (1).
Armstrong (2) has proposed a DOMS Model which includes a series of events occurring
from DOMS to recovery. It is proposed that DOMS causes damage to the sarcolemma,
the muscle cell membrane. This damage results in the release of biochemical markers of
muscle damage (e.g. lactate dehydrogenase (LDH), creatine kinase (CK), and myoglobin
(Mb). The inflammation process begins as a precursor to full recovery of damaged
muscle fibers. Inflammation, indicated by the blood marker C-reactive protein (CRP),
denotes the onset of the healing process (2).
In 2002, the NormaTec Pneumatic Compression Device (NTPCD) was introduced to
the world of external compression. It was backed as an FDA cleared medical device
which yielded highly effective results for patients who had been diagnosed with
peripheral vascular diseases (PVD) (3). The NTPCD differentiates from other external
compression devices because of its patented peristaltic pulse pneumatic waveform. This
peristaltic pulse was a major advancement that went beyond the existing and already
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established inflation and deflation strategies (non-sequential, sequential, and sequential
gradient) used in the 1960s to 1980s (3).
In 2007, NT extended its technology from clinical medicine to sports medicine as a
recovery tool for athletes. The sequential pulse technology compression (peristaltic pulse
pneumatic waveform, in the sports medicine jargon) is based on normal physiology and
combines three distinctive massage techniques to speed the body’s natural recovery
process (3). The first technique is pulsing. Sequential pulse technology uses pulsing, or
dynamic compression, to more effectively mimic the muscle pump of the legs and arms.
This dynamic compression greatly enhances the movement of fluid and metabolites out
of the muscles after intense workouts. The second technique is gradients. Sequential
pulse technology uses gradient hold pressures to prevent body fluids from being forced
down to the feet by the pulsing actions described previously. The gradient hold allows
maximum pressure to be delivered throughout the entire limb and the effectiveness of the
pulsing action is not curtailed at the top of the limb. The third technique is distal release.
Extended static pressure can not only be detrimental to the body’s natural circulatory
flow, but to the limb where the pressure is applied as well. The sequential pulse
technology, however, releases the held pressures placed on the limb once they are not
needed to prevent backflow of blood. In releasing the held pressure in each zone as
quickly as possible, each portion of the limb gains maximal recovery time without a
significant pause between compression cycles (4, Appendix A).
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Statement of the Problem
Research is needed in order to determine if the NT recovery unit is effective in the
reduction of muscle inflammation after long distance running. If the NT recovery unit can
speed recovery as well as reduce the effects of DOMS on athletes, this may allow for
athletes to enhance their training by helping them recover quicker and by allowing them
to train harder.
Purpose of the Study
The purpose of this study was to measure the effects of intermittent pneumatic
compression (NT) on the muscle inflammation marker C-reactive protein (CRP) and
DOMS in trained athletes after long distance running.
Hypothesis
NT treatment will reduce inflammation, as indicated by the blood marker C-reactive
protein (CRP), and reduce delayed onset muscle soreness (DOMS).
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CHAPTER II
LITERATURE REVIEW
The literature review discusses DOMS and exercise-induced muscle damage, potential
effects of massage and other recovery treatments (relatively older forms of treatment),
and intermittent pneumatic compression (relatively newer form of treatment) on DOMS
and exercise-induced muscle damage.
DOMS and Exercise Induced Muscle Damage
Milias et al. (5) sought to determine if a relationship existed between platelet activator
factor (PAF) and eccentric exercise induced muscle damage. The subjects consisted of 13
healthy, active males who had not participated in any kind of resistance training for a
minimum of six months before participating in the study.
Subjects performed six sets of six repetitions (maximum eccentric actions of the
elbow flexors) with their non-dominant arm using a motorized muscle dynamometer with
a one minute rest period between sets. Venous blood samples were collected from the
dominant arm immediately prior to, and following the non-dominant arm exercise.
Additional blood samples were taken 2, 24, 48, 72, and 96 hours following the exercise.
PAF, C-reactive protein(CRP), creatine kinase (CK), fibrinogen, lactate dehydrogenase
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(LDH), complement C3, and whole blood level leukocytes (including their subsets) were
determined.
The results indicated CK, LDH, leukocytes, and PAF were the only biochemical
markers which elevated and showed statistically significant differences following
exercise. The authors concluded a possible role of PAF in the mechanism of exercise
induced muscle injury and suggested future research investigate the exact features of PAF
in its role as a mechanism of exercise induced muscle injury, and whether it could be
utilized as a new marker of muscle damage (5).
Nosaka et al. (6) investigated DOMS and enzymes indicating muscle damage
following eccentric exercise. They enrolled 110 healthy males, mean age 23 years, who
had not been involved in a resistance exercise training program. Subjects were placed in
one of two groups based on the number of eccentric exercises they were able to perform.
The first group (N=50) performed 12 eccentric exercise actions. The second group
(N=60) performed 24 eccentric exercise actions.
Muscle soreness was measured with a visual analog scale indicating “no pain” to
“unbearable pain” based on three assessments: palpating over the elbow flexors, and
flexing and extending the elbow joint in a full range of motion. Soreness developed on
day one following exercise and peaked two to three days after exercise for both groups.
Time course changes in soreness were similar in palpitation, flexion, and extension.
However, peak soreness values were significantly smaller for flexion compared to
palpitation or extension. There were no significant differences between the first group
and second group for palpitation and flexion soreness, but the second group had
significantly higher extension soreness values three and four days after exercise
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compared to the first group. Peak soreness values were similar for the first and second
group for palpitation and flexion soreness. However, the second group showed
significantly higher peak extension soreness values compared to the first group. A
Palpitation soreness did not correlate significantly with any indicators, however,
extension and flexion soreness revealed a weak (r < 0.32) but significant correlation with
the other indicators.
Maximal isometric force, relaxed and flexed elbow joint angle (RANG and FANG),
upper arm circumference, and CK were measured before, immediately after, and every
day after for four consecutive days following the exercise. The results indicated no
significant difference in the pre-exercise maximal isometric force between the first group
(12 eccentric exercise actions) and second group (24 eccentric exercise actions). Maximal
isometric force dropped about 58.1% for the first group and about 47.1% for the second
group immediately after exercise. The force deficit was significantly larger for the second
group compared to the first group. Four days after exercise, maximal isometric force had
recovered to about 73.1% of the pre-exercise value for the first group which was
significantly larger than the second group which was about 52.5% of the pre-exercise
value at the same time point.
The results for the elbow joint angles for RANG showed a significantly larger mean
decrease immediately following exercise in the second group compared to the first group.
Four days post-exercise, RANG was found to still be significantly smaller than the preexercise level for both the first and second groups. However, the amount of decrease
from baseline was significantly larger for the second group compared to the first group.
The mean increase in FANG following the second group was significantly larger
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compared to the mean increase in the first group. Four days post-exercise, FANG was
found to be still significantly larger than pre-exercise levels for both the first and second
groups. However, the amount of increase from baseline was significantly larger in the
second group compared to the first group.
Upper arm circumference significantly increased immediately following exercise for
both the first and second groups. The upper arm circumference continued to increase and
peaked three to four days post-exercise in both groups but the greatest value in the second
group was significantly (P<0.01) larger compared to the first group.
Plasma CK activity significantly increased and peaked three to four days post-exercise
in both groups. However, CK in the second group was significantly higher compared to
the first group.
It appeared the degree of DOMS associated with eccentric exercise was not affected
by the severity of muscle damage. Likewise, levels of muscle soreness either have little
or no correlation with other commonly used muscle damage indicators. Thus,
preventative or treatment measures for DOMS are not the same as preventative or
treatment measures for muscle degeneration and regeneration. The authors further
suggested that finding preventative or treatment measures which reduce strength loss or
plasma CK responses are not necessarily effective in treating DOMS and that in the
absence of DOMS, muscle damage and the loss of muscle function will persist. So using
DOMS to judge the degree of muscle damage is not recommended. However, when used
jointly with other indicators of muscle damage, DOMS can provide further evidence of
changes within the muscle (6).
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Lee, Clarkson (7) investigated 60 untrained healthy males and females ages 18 to 30
years who had not previously been involved in a weight training program for six months
for the determination of total resting glutathione levels. The first 30 test subjects had
three baseline blood draws measured for total glutathione, CK, and myoglobin (Mb).
Maximal voluntary isometric contraction (MVC) and relaxed arm angle (RANG) were
also measured. From the initial 60 test subjects, only 17 subjects were included in the
study’s inclusion criteria of total glutathione (<2.5 or ˃3.8 μmolL-1). The subjects who
were included in the <2.5 range were put into a low glutathione group (LG, N=8) while
the subjects in the ˃3.8 range (HG, N= 9) were put into a high glutathione group.
The exercise protocol consisted of the subjects performing one set of 50 maximal
eccentric contractions, three second duration with 12 second rest in between, on a
modified preacher curl machine. Using a strain gauge attached to the modified preacher
curl machine, MVC was assessed with three trials. Using a goniometer to measure elbow
joint angles, RANG was measured with the subject’s arm hanging at his or her side
passively with the wrist in a neutral position. The arm was marked at the wrist, elbow,
and shoulder with a skin marker to ensure day to day measurement reproducibility.
RANG was determined by taking the mean of the three trials.
Baseline measures determined no difference in resting plasma glutathione and CK
levels over the two baseline days. The intraclass R-value over the two days for CK was
0.80 for the 17 subjects. A significant group, time, and group by time interaction was
found for MVC.The RANG results revealed no significant group effect however, there
was a significant main effect across time and in the group by time interaction.
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There was no significant group effect; but there was a significant time effect and
group by time interaction in CK response. There was a significant group, time, and group
by time interaction in Mb levels. There was a significant group, time and group by time
interaction for Glutathione. There was also no significant relationship between
Glutathione and CK in LG or HG.
The authors concluded that subjects with low plasma Glutathione levels had a smaller
plasma CK and Mb response and recovered faster from eccentric exercise than subjects
with high plasma Glutathione levels. It was suggested that subjects with low plasma
Glutathione had a lowered inflammatory response (7).
Chleboun et al. (8) enrolled 11 females, ages 19-22 years, who had not been involved
in a resistance exercise program which included the elbow flexors for 6 months before
the study. Isometric MVC, were determined using the elbow flexors from three separate
repetitions on three different days and the subject rested two minutes between each
contraction. Muscle soreness, isometric strength, stiffness and swelling measurements
were taken three times before exercise, post exercise and daily for five days and every
other day during the 2nd week following the exercise bout. The authors used a five point
scale (0 = no pain; 1 = pain on palpation only; 2 = mild pain with full flexion or extension
of the elbow; 3 = significant pain with full flexion or extension of the elbow; 4 = constant
pain) to measure muscle soreness.
The authors measured stiffness by using an apparatus which moved by a stepper motor
in four degree steps. The motor moved from a resting position of 90 degrees to full elbow
extension and it was programmed to record angle as well as torque 12 seconds after each
of the 4 degree steps. This allowed for 80-90% of stress relaxation.
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A second measure of stiffness was measured by using relaxed arm angle. The amount
of swelling in the upper arm was measured by using arm circumference and muscle
compartmental volume by cross-sectional ultrasound imaging. The average peak soreness
resulted in a score of 2.9 on day two. MVC decreased immediately after exercise and
reached its lowest point on day one post exercise. Strength remained significantly
decreased 11 days post exercise. The volume of the flexor muscles exhibited a significant
increase over pre-exercise volumes. Stiffness increased immediately after exercise and
remained elevated for the next five subsequent days.
It was determined that delayed onset of swelling did not account for the immediate
rise in muscle stiffness. It was also determined that the increased stiffness was related to a
change in calcium homeostasis from muscle injury. This suggests stiffness coincides with
the flexor muscles returning to normal volume, which further indicates that the return to
normal values from stiffness may be a result of muscle edema (8).
Nosaka, Clarkson (9) enrolled 14 males, 20-24 years of age, who had never been
involved in a weight training program. Six of the 14 subjects were chosen at random to
be scanned using an MRI. The subjects performed 24 maximal eccentric actions utilizing
the elbow flexors of their non-dominant arm on a modified arm curl machine. The
subjects were evaluated for maximal isometric force (MIF), range of motion (ROM),
circumference (CIR), soreness (SOR), ultrasound images (USG), MRI, CK, aspartate
aminotransferase (AST), lactate dehydrogenase (LDH), interleukin - 1α (IL-1α),
interleukin – 1 β (IL-1β), interleukin – 2 (IL-2), interleukin – 6 (IL-6), tumor necrosis
factor – α (TNF-α), CRP, cortisol and zinc. Measurements were taken immediately
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before and after exercise and for five days post- exercise, except the MRI images were
taken on day 1, 3, 6 pre-exercise and day 10, 23, 31, and 58 post-exercise.
MIF was measured on an arm curl machine using a transducer which was connected to
a digital indicator. The MIF was measured at an elbow joint angle of 90 degrees. Using a
goniometer, the elbow joint angle ROM was evaluated using flexed (FANG) and relaxed
(RANG) at the elbow joint. After obtaining FANG and RANG measurements, ROM was
calculated by subtracting FANG from RANG. Muscle soreness was assessed by using an
analog scale, based on the subject’s perception, of no pain to very painful. CIR was
assessed using the upper arm at four different sites (4, 6, 8, 10 cm) above the elbow joint
with the subject’s arm hanging down by their side.
All subjects were assessed using USG (7.5 MHz linear probe) on the same four sites
used in the CIR measurements to obtain transverse scans of the brachialis and biceps
brachii. MRIs were taken from the upper arm using the elbow joint as a landmark for
consistent scanning. Three circular areas of interest, which indicated an increase in signal
intensity, were set in the transverse section of the biceps brachii or brachialis. The mean
value from the three ROI was used as a reference during measurement, and was placed in
the center of the triceps brachii.
There was a significant drop in MIF (approximately 55%) in pre-exercise levels
immediately post exercise. Five days post exercise, MIF was still 70% below pre-exercise
levels. There was also a significant decrease in ROM immediately following exercise
with no indication of recovery three days after exercise with a gradual recovery
following. There was no significant difference in SOR levels between palpation and
extension of the elbow joint. There were also no significant differences in all four upper
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arm circumference measurements. In eight of 14 subjects, USG showed an increase in
echo intensity in the brachialis three to five days post exercise. Increased echo intensity
was shown by six subjects in both the brachialis and biceps brachii. USG also revealed an
increase (0.6 cm – 2.2 cm) in muscle thickness with a maximum increase three to four
days post exercise which remained unchanged for five days after exercise.
The elbow flexor muscles showed enlargement in the cross sectional area with
profound increases in signal intensity at three days post exercise. CK, AST, and LDH
revealed no significant increase as the changes over time among all the enzymes were
similar. No significant changes were observed in CRP, cortisol and zinc following
exercise. The authors concluded that in spite of similar responses in exercise induced
muscle damage and inflammatory responses accompanying infection or tissue injury,
there are identifiable differences overall from the classical observance of typical tissue
damage/repair processes (9).
Hosoi et al. (10) enlisted 15 male recreational runners, 41-46 years old, in good health
with predominantly daily sedentary employment to run a marathon. Following the
marathon, participants adhered to their normal daily routine; however, due to muscle
soreness, participants did little running in the first week. The subjects were unable to
resume their normal training activity for at least two weeks after the marathon.
Two weeks before subjects participated in the marathon, each was required to perform
a maximal exercise test and body impedance was used to determine body fat percentage.
Venous blood samples were obtained to establish baseline levels on the morning of the
marathon. The first post race blood sample was drawn within five minutes of each
subject’s finish and subsequent samples were taken on days 1, 2, 3, 7, and 14 after the
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marathon. Measures included: total cholesterol (TC), triglycerides (TG), HDL-C, LDL-C,
free fatty acids (FFA), lactate dehydrogenase (LDH) and hematocrit (Hct).
Hematocrit increased significantly from baseline (43.1%) to post race (44.0%). In
days one, two, and three, hematocrit levels were within 0.3% of baseline. Plasma TG
levels significantly elevated immediately following the marathon (7%); but, after day one
and two of recovery, levels fell significantly (28%) below baseline. After one week, TG
levels returned to baseline. LDL-C levels were not significantly affected by the marathon,
but gradually fell significantly below baseline levels for three days, returning to baseline
after one week. HDL-C levels increased 14% the first day following the marathon and
remained significantly elevated for three days, gradually decreasing to baseline. TC
increased slightly following the marathon and then significantly fell below baseline after
two days, returning back to baseline within one week. TC/HDL-C ratio reduced 9 %
immediately following the marathon and the ratio declined 16% below baseline for three
days, reaching baseline levels after two weeks.
Average CK levels post race tripled from baseline with a continual increase reaching a
15-fold peak after the first day, falling to baseline levels after one week. LDH levels
doubled from baseline post race and declined linearly in a two week period towards
baseline. Post race CK and LDH levels were significantly correlated over time (average
r=+.71). FFA levels rose by a factor of 10 immediately post race with a rapid decline
after the first day. With the decreasing values, FFA remained elevated, when compared to
baseline, for two days.
It was determined, through this study, that prolonged strenuous exercise in
recreational runners produces beneficial changes in lipid blood profiles. However, these
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changes were only significant for three days. Further, evidence of exercise-induced
muscle damage occurring during the marathon returned to baseline levels within two
weeks (10).
Schwane et al. (11) enrolled seven healthy males ages 19-21 years who were active in
aerobic activities but none were highly trained. The subjects performed three treadmill
exercises in a specific order: VO2 max test, level run, and downhill run. Six subjects
performed the three outlined consecutive tests separated by six to seven days. The
seventh subject had a 23 day separation between the first two sets and a 14 day separation
between the second and third tests.
Following the VO2 max, all subjects had a short period of recovery. The subjects ran
on the treadmill at 0% incline during which their VO2 was measured. The speed attained
from the recovery run was used on the level and downhill tests. The level test was run at
0% incline and the downhill test was run at -10%. Subjects ran intermittently for 45
minutes with two minute rest periods interspersed between five minute runs. During the
last minute, within each 5 minute bout in the level and downhill tests, VO2 was measured.
The oxygen requirement for each subject within the exercise was calculated using the
average of the last minute within each running bout.
Blood was drawn from the antecubital vein immediately prior to exercise and five
minutes 24 hours, 48 hours and 72 hours after the level and downhill runs to determine
creatine, phosphokinase (CPK) and lactate dehydrogenase (LDH). Additionally, total and
differential hematocrit (Hct) and white blood cell (WBC) counts were obtained. Muscle
soreness was evaluated based on a four point scale (0 = complete absence of soreness; 1
= light pain felt only on palpation; 2 = moderate pain with some stiffness and/or
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weakness during movement; 3 = severe pain that limits range of motion). The ratings
were based specifically on the anterior and posterior leg muscle groups (gluteal,
hamstring, quadriceps).
During the level run, VO2 and heart rate were significantly (P < 0.001) higher
compared to the downhill run; however, there was no difference in stride frequency
between the two tests. Also, during the level run, muscle soreness was only reported in
isolated muscle groups. However, it was found through the duration of post exercise, that
there was no significant increase in muscle soreness found in any muscle group of the
anterior and posterior part of the leg.
Muscle soreness after downhill running was experienced in several different muscle
groups. Post exercise muscle soreness ratings had a significant increase compared to preexercise for the anterior and posterior part of the leg. Plasma CPK was not significant
following the level run; but during the downhill run, 24 hours post exercise CPK values
were significantly elevated compared to pre-exercise values. At 48 hours post exercise,
CPK values were not significantly different from 24 hours post exercise, nor from preexercise values. The association (r = 0.53) between plasma CPK and muscle soreness
over time was significant.
There was no significant change from pre to post exercise at any point during the
study between the level and downhill run, nor was there a correlation (p= - 0.05) between
muscle soreness and LDH values. Additionally, there were no changes observed in preexercise LDH values in either level or downhill running compared to post exercise LDH
values.
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There was only one significant change in WBC from pre-exercise to post exercise
immediately following the level run and only one significant change in WBC count
during the downhill run in which there was a decrease in monocytes 48 hours post
exercise. The largest change in Hct occurred in one subject 24 hours post exercise during
the downhill run, -18% pre-exercise value. Changes in Hct levels were observed to be
fairly stable in the other six subjects.
It was determined that delayed onset muscle soreness (DOMS) caused by downhill
running did not increase WBC indicative of inflammation. It was further determined
structural changes occurring in muscle tissue as a result of eccentric muscle contractions
produce plasma enzyme activities and DOMS (11).
Millar et al. (12) recruited 21 subjects who were divided into a control group and an
exercise intervention group, matched by age and gender, to determine the effects of
aerobic exercise on aspartate aminotransferase (AST), pain, strength, alanine
aminotransferase (LT), creatine kinase (CK), and range of motion (ROM). The test
subjects all performed eccentric hamstring contractions using a Biodex isokinetic
dynamometer consisting of five sets of 10 repetitions. Active knee extension, pain
ratings, AST, isometric hamstring strength, ROM, AST, and CK were all assessed before
exercise as well as 24, 48, and 72 hours following exercise. Those in the exercise group
walked on a motorized treadmill at 50% of their maximum heart rate for 20 minutes at 3,
24, and 48 hours following exercise.
No significant differences were found between the control and exercise intervention
groups. A trend analysis was run and significant differences were found in the response
to CK, ROM, and strength. The exercise intervention group continually lost ROM until
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day three with less ROM compared to the control group. The exercise intervention group
also experienced a more rapid rise in CK compared to the control group. The authors
concluded that aerobic exercise used as an intervention did not alleviate the symptoms of
DOMS and based on the trend analysis, it may even slow down the normal healing
process (12).
Effects of Massage on DOMS
Zainnuddin et al. (13) tested the hypothesis that if massage was applied after eccentric
exercise, DOMS would be effectively alleviated without affecting muscle function. They
enrolled 10 healthy subjects, five women and five men, ages 22-24 years, who had no
history of upper arm injury nor did they have any experience in resistance training. An
arm to arm comparison model was used in which one arm served as the control and the
other served as the treatment condition. Dependent variables measured on the exercised
arm were maximal isometric and isokinetic voluntary strength, range of motion, upper
arm circumference, plasma CK, and muscle soreness (VAS, 0 indicating no pain and 100
indicating extremely painful).
The subjects performed 10 sets of six maximal isokinetic eccentric actions involving
the elbow with each arm with a two week separation between tests. A standard sports
massage was administered by a professional massage therapist who had been working
with the Australian football club for several years. One arm was massaged for 10 minutes
three hours after the eccentric exercise was performed, while the other arm received no
treatment. Massage techniques used were deeply applied clearing techniques with palmar
(petrissage) and finger (effleurage) pressure and strokes to the muscle.
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The results indicated no significant difference between baseline maximal isometric
and isokinetic strength between the massage and control arms. Similarly, no significant
difference existed between peak torque and total work during eccentric exercise. No
significant differences were observed between maximal isometric torque at an elbow
angle of 90 degrees and 30 degrees between the massage and control arms. The isometric
torque values decreased about 60% from the pre-exercise values immediately post
exercise and remained at these decreased values for two days; torque returned to the preexercise level by 10 days post-exercise. There was no significant difference between the
massage and control arms for changes in isometric torque over time.
The changes in maximal voluntary isokinetic torque were similar to those found in the
isometric torque throughout the post-exercise period. No significant difference was
evident between the massage and control arms for any of the velocities tested.
Additionally, the isokinetic torque values returned to pre-exercise levels by day 10 for
both conditions. No significant differences were evident in the pre-exercise ROM values
between the massage and control arms. Immediately post-exercise, ROM decreased
significantly by about 30% from the baseline and did not recover over the next four days.
The upper arm circumference significantly increased during the post-exercise period
in both conditions, however, the massaged arm showed a significantly smaller increase as
compared to the control arm. While plasma CK activity significantly increased in both
conditions post-exercise, there were significantly smaller CK increases in the massaged
arm as compared to the control arm. Additionally, the massage condition peak value was
36% lower compared to the control condition.
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Peak soreness occurred one to three days post-exercise, whereas peak soreness
occurred four days post-exercise for the elbow joint extension and all reports of soreness
were resolved seven days post-exercise. Significant differences existed between the
massage and control conditions in regard to peak soreness with palpitation and elbow
joint extension. Massage resulted in a 20% to 40% decrease in muscle soreness compared
to the control. The authors concluded that massage was effective in reducing the
magnitude of DOMS, swelling, and plasma creatine kinase. However, massage seemingly
had no positive effects on muscle strength or ROM (13).
Moraska (14) enrolled 317 finishers in a 10 km running race. A questionnaire
recorded the following information: race finish time, demographic information and
perceived exertion during the run. The participants rated their muscle soreness on VAS
with 0 being absence of muscle soreness and 10 indicated extreme muscle soreness.
Immediately following the race, subjects were randomly assigned a student massage
therapist and were blinded to their educational training of their massage therapist.
Massage students with 450, 700 or 950 hours in didactic massage therapy training
administered massage in all sessions. Massage was administered to test subjects after the
10 km race for 12 to 15 minutes, within 15 to 60 minutes after completing the race.
Student therapists were not bound to a specific protocol and were able to use massage
strokes and techniques deemed appropriate for each subject’s needs. However, the
primary technique used was effleurage, which consists of applying deep flushing strokes
to the areas of concern to the race participant.
It was determined that there were no significant differences among age (P = 0.90),
time and perceived exertion among the treatment groups. Average muscle soreness was

19

rated a 4.4 among all treatment groups. Participants who received massage from student
therapists who accumulated 950 hours of training reported significantly greater
improvement in muscle soreness throughout the study compared with those receiving
massage with student therapists accumulating 700 or 450 hours of training.
Gender had no affect on muscle soreness throughout the study. In addition, at the 24
hour post race time, muscle soreness for the participants receiving massage from the
student therapists who accumulated 950 hours (2.4 pain rating) of training continued to
report significantly lower muscle soreness ratings as compared to the subjects receiving
massage from the student therapists with 700 (3.7 pain rating) or 450 (3.6 pain rating)
accumulated training hours.
Post hoc analysis at the 48 hour post race point in the study, revealed a trend for a
lower muscle soreness rating in the group of student therapists with 950 massage training
hours. Results indicated a significant improvement in muscle soreness immediately after
the 12-15 minute massage compared with pre-massage values. Immediately following
post massage, average muscle soreness reported for all three treatment groups was 3.1. It
was determined that the amount of therapist training impacted the effectiveness of using
massage as a post race recovery tool. The greatest reduction in muscle soreness was
achieved by the student therapists who had accumulated 950 hours of training compared
with those with 700 or 450 accumulated training hours (14).
Wiltshire et al. (15) sought to determine if sport massage aided muscle recovery
following exercise by increasing blood flow in order to improve lactic acid removal by
recruiting 12 healthy males, ages 23-26 years. Subjects were in the supine position
throughout the duration of the experiment with the forearm positioned at heart level in
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each of the three testing conditions. Time allowed between trials for all variables being
measured to return to original baseline levels was about 15 to 20 minutes before the
initiation of the next trial.
The three experimental protocols were arranged such that 11 of the 12 test subjects
performed all three protocols on the same day. The three experimental conditions were
counterbalanced between subjects. Subjects were required to perform three preliminary
maximal isometric hand grip (IHG) contractions by using a calibrated hand grip
dynamometer with a one minute recovery between contractions. Maximum voluntary
contraction (MVC) was the highest of the three trials. Once MVC was established,
subjects squeezed IHG continuously for two minutes at 40% of their MVC at the
beginning of the testing protocol. Following IHG exercise there were two types of
recovery: passive and active. In the passive recovery protocol, the subject laid quietly
following the two minute IHG with their forearm at rest for 10.5 minutes. The active
recovery protocol consisted of subjects laying quietly for 30 seconds with their forearm at
rest. Following the 30 second rest, subjects began rhythmic forearm contractions at 10%
of their MVC for 10 minutes. The subjects also had a duty cycle of 1:2 contraction
relaxation coordinated with a metronome.
For the post IHG massage protocol, following the subject’s two minutes of IHG, the
subject rested for 30 seconds lying quietly with their forearm at rest in which forearm
massage started. Massage was administered by a single registered massage therapist with
13 years of sport massage experience. Massage consisted of effleurage strokes during the
first and last 2.5 minutes of therapy with petrissage strokes in the five interim minutes of
therapy.
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Before initiating the experimental protocols all test subjects had their right hand
heated using a hydrocollator heating pad for 10 minutes. Following the hand heating, a
blood sample was obtained for arterial lactic acid and hemoglobin during the
experimental protocol.
Heart rate was measured using standard CM5 ECG placement and mean arterial
pressure (MAP) was measured using finger photoplethysmography, both measured beat
to beat. The brachial artery mean blood velocity (MBV) measurements were obtained
beat by beat on the experimental arm. A pulse Doppler ultrasound probe was used at an
operating frequency of four MHc.
The results for MBV indicated an uninterrupted pulsatile flow during passive rest.
Active rest results indicated a negative brachial artery blood velocity. Petrissage and
effleurage massage strokes at first decreased blood velocity followed by an increase in
blood flow velocity during the brief pauses by the massage therapist.
IHG strength declined over time in the subject’s ability to maintain 40% of MVC. No
difference was detected between MAP or HR. The MAP increased more in the passive
recovery compared to massage and active recovery, by the end of the IHG. During active
recovery, MAP remained higher than massage during the first 2.5 minutes of post
exercise achieving statistical significance compared to passive recovery.
Immediately following IHG, VO2 was noted to be greater in passive recovery than
both active and massage recovery. Active recovery was greater than massage recovery.
The VO2 was substantially greater in active recovery compared to both passive and
massage recovery. Following IHG, there were no significant differences in recovery
conditions after four and a half minutes. Total forearm blood flow following post IHG
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was significantly reduced in massage recovery compared to passive recovery. However,
it was not significant compared to active recovery. Post IHG active recovery indicated no
difference from passive recovery. Lactic acid post IHG was found to be about 17% lower
in active recovery compared to passive recovery but was not statistically significant.
Hydrogen did not differ between conditions.
It was determined that severe impairment of blood flow occurs during the massage
stroke, resulting in a decrease of muscle blood flow in the recovery period following
strenuous exercise. Active recovery showed similar effects. The authors stated the
decreased blood flow is responsible for impaired lactic acid removal from the exercised
muscle. It appears that active recovery does not improve muscle blood flow following
exercise; but, it does appear to increase lactic acid uptake by the muscle, improving
lactate removal from muscle tissue. The authors noted that sports massage would not be
optimal in situations where acute bouts of repeated exercise are occurring and where
lactic acid builds up (15).
Hinds et al. (16) compared a control condition against massage to determine if
massage affected femoral artery blood flow (FABF), muscle temperature (MT), skin
temperature, and skin blood flow (SKBF) following quadriceps exercise. The subjects
consisted of 13 males, ages 20-22 years, who participated in an exercise bout consisting
of three, two minute concentric quadriceps exercises followed by either three, six minute
deep effleurage and petrissage massages or a 12 minute rest period (control). Blood
lactate concentration (BLa), FABF, MT, heart rate, blood pressure, skin temperature, and
SKBF were taken at baseline, immediately following exercise, and at the midpoint as
well as the end of the massage or rest periods.
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The results indicated significant differences for all the variables over time due the
exercise compared to baseline. Massage was found to not significantly elevate heart rate,
BLa, FABF, blood pressure, or MT compared to the control. Skin temperature and SKBF
significantly elevated after massage compared to the control. The authors concluded that
any increases in SKBF could potentially redirect blood flow away from recovering
muscle tissue, thus questioning the ability of massage to aid in post exercise recovery
(16).
Haas et al. (17) examined the effectiveness of using immediate compared to delayed
compressive massage-like loading on inflammatory cell infiltration as well as peak
isometric torque recovery following eccentric type exercises. White New Zealand rabbits
(N=18), which were skeletally mature, were used in the study by adapting peroneal nerve
cuffs to the hind limb in order to stimulate the tibialis anterior muscles. Following a bout
of eccentric exercise the rabbits were randomly assigned to one of the three massage-like
compressive loading protocols for 15 minutes for four consecutive days. The first
protocol started immediately following exercise, the second started 48 hours following
exercise, and the third protocol consisted of no massage-like compressive loading to act
as a control. A relationship between torque angle was gathered from 21 joint angles
before and after eccentric exercise as well as following four consecutive days of either
massage-like compressive loading or no massage-like compressive loading. Following
the final treatments immunohistochemical sections as well as muscle wet weights were
gathered.
The results indicated an average decrease in peak isometric torque output following
eccentric exercise of about 38-64%. Immediate application of massage-like compressive
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loading was determined to have the most considerable peak torque recovery. Differences
were found in torque recovery among delayed massage-like compressive loading and
control, immediate and delayed massage-like compressive loading, and immediate
massage-like compressive loading and control. An immunohistochemical analysis was
performed and indicated a 39.3% increase in the amount of RPN3/57 (antibody which
detects uncharacterized antigens found on T lymphocytes, neutrophils, platelets, and
thymocytes) and a 366.0% increase in CD11b (an antibody used mainly to identify
neutrophils but it can also identify blood monocytes, macrophages, bone marrow cells,
and other granulocytes) positive cells among the immediate and delayed massage-like
compressive loading. The torque angle indicated a difference for immediate and delayed
massage-like compressive loading compared to the control. Peak isometric torque angle
was determined and indicated a rightward shift (9.8-10.2 degrees) following exercise
compared to the pre-exercise angle. The control, immediate, and delayed massage-like
compressive loading indicated a leftward shift in peak isometric torque angle compared
to the pre-exercise angle. The authors concluded that immediate massage-like
compressive loading following exercise was more beneficial than delayed massage-like
compressive loading in balancing inflammatory cell infiltration and in recovering muscle
function. The authors found that by delaying the administration of massage-like
compressive loading following eccentric exercise there was a greater amount of
infiltration of immune cells as well as a greater amount of edema (17).
Weerapong et al. (18) conducted a meta-analysis and evaluated three different aspects
of massage: types of massage, possible mechanisms for effect, and effects on
performance, recovery, or muscular injury prevention. They concluded more research is
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needed to determine if the effects of massage are beneficial. Furthermore, the authors
concluded that the different types of massage, the appropriate timing of massage on
performance, recovery from injury, or as an injury prevention method all need to be
further examined. From their research, Weerapong et al. posed the following seven
questions to initiate further research (18):
1. “Can massage increase blood flow, muscle temperature, neuromuscular
excitability or muscle flexibility?”
2. “Can massage increase performance in sprinting, jumping, or endurance athletic
events?”
3. “What type of massage can produce benefits?”
4. “How long should massage be applied?”
5. “When should athletes receive massage?”
6. “Are the effects of massage universal or are they specific to each massage
therapist?”
7. “Is the cost and time for massage appropriate when a warm-up or cool-down may
be as, or more, effective?”
Weerapong et al. (18) suggested an additional six points on which future research studies
on massage should consider to overcome limitations:
1. “An appropriate control group should be provided.”
2. “The ideal control group for a massage study should be a passive therapy
modality. This is where the participants receive the same attention in terms of
time from the therapists as the massage group.”
3. “The therapists should not apply any pressure on the muscle.”
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4. “Some physiotherapy equipment might be appropriate to incorporate in the study
such as a sham shortwave diathermy.”
5. “Studies should utilize a counterbalance design in order to minimize the
difference responses of individual participants.”
6. “Appropriate outcome measures and massage techniques should be used in the
study.”
Alternative Recovery Treatments on DOMS
Mekjavic et al. (19) recruited 24 healthy males, 20-35 years, to investigate if
hyperbaric oxygen therapy (HBOT) would speed muscle recovery following exerciseinduced injury to the muscle. Subjects were assigned randomly to a HBOT group or a
placebo group. Before performing the workout each subject completed a maximal
isometric strength test on the right elbow flexor. Following the maximal isometric
strength test the subjects then performed the workout which induced DOMS. The
workout consisted of a high force eccentric workout using the elbow flexor muscle group.
Following the workout the subjects were exposed to either a normoxic (0.2 ATA) mixture
or a hyperoxic (2.5 ATA) mixture for an hour over seven continuous days. During one of
their oxygen therapies, each subject had a transcutaneous PO2 electrode which was
attached over the biceps brachii via the skin in order to determine the amount of tissue
oxygenation by the oxygen therapy. The subjects used a VAS to rate their perceived
muscle soreness from “no pain at all” to “worst pain I could possibly feel.”
The results indicated a significant decrease in isometric strength from pre-exercise to
the post-exercise in both the placebo and HBOT groups. Over the recovery period no
significant difference was found in the rate of muscle strength recovery between the
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groups. No significant difference between the groups was found in perceived soreness
with soreness levels peaking 48 hours post exercise. Additionally, increases in arm
circumference caused by exercise were similar between groups. The authors concluded
that HBOT was not effective in the treatment of DOMS and the use of this therapy is not
warranted and athletes should be discouraged from using it (19).
Pointon et al. (20) examined the effects of cold water immersion (CWI) on recovery
following simulated collision sport exercise. The study consisted of 10 male rugby
players, ages 19-23 years, who performed three sessions including two, 30 minute
intermittent sprint exercises (ISE) consisting of 15 meter sprints every minute followed
by self-paced exercise bouts of walking, hard running, or jogging making up the rest of
the minute. Randomly incorporated into the ISE were three testing conditions: no
tackling with passive recovery (the control), tackling with passive recovery, and tackling
with a 20 minute CWI recovery. During every sixth rotation, the test subjects received
shoulder led tackles to the lower body while performing five, 10 meter sprints on each
exertion. The variables recorded in the study were sprint times and distances covered in
the ISE, electromyogram, voluntary activation, maximal voluntary contraction, and
perceived soreness. Venous and capillary blood markers were measured before and after
exercise to establish baseline measures, immediately following recovery as well as two
and 24 hours post recovery for metabolites indicating muscle damage.
Results indicated tackling with CWI significantly increased voluntary action,
electromyogram, and maximal voluntary contraction immediately following recovery.
Tackling with CWI had no effect on the elevation of DOMS markers but blood lactate
was reduced significantly following recovery compared to tackling with passive
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recovery. The results further indicated CWI reduced perceived muscle soreness two hours
following recovery compared to tackling with passive recovery. The authors concluded
that with bodily collision, the ability to perform exercises decreases, CWI aids in an
accelerated recovery of voluntary action, electromyogram, and maximal voluntary
contraction, as well as promotes an improved perception of muscle soreness and
contraction following exercise which is collision-based (20).
Mawhinney et al. (21) sought to determine if cold (eight degrees Celsius) and cool (22
degrees Celsius) water immersion affects cutaneous and femoral artery blood flow
following exercise. The study consisted of 12 men, age 21-30 years, who completed a
cycle test at 70% of the subject VO2 max until the desired core body temperature of 38
degrees Celsius was achieved. Once the desired core body temperature was achieved, the
subjects were immersed into either cold or cool water while semi-reclined up to the iliac
crest for 10 minutes or participated in a seated rest (control). The variables measured in
the study before immersion, and up to 30 minutes following immersion were thigh skin
and rectal temperature, superficial and deep muscle temperature, blood flow to the calf
and thigh using laser Doppler flowmetry, as well as blood flow of the superficial femoral
artery using duplex ultrasound. Calculated variables during the study included vascular
conductance indices such as flux and blood flow, heart rate, and mean arterial pressure.
Results of the study indicated similar rectal temperature reductions (a range of 0.6
degrees to 0.7 degrees Celsius) in all three of the trials. During recovery following
exercise, the average skin temperature of the thigh was 25.4 degrees for the cold water
trial, 28.2 degrees for the cool water trial, and 33.8 degrees for the control trial. Similarly,
the lowest recorded recovery muscle temperature during the study was found in the cold
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water trial. Conductance of the femoral artery 30 minutes following immersion in both
the cold and cool water trials was lower in temperature (about 55%) compared to the
control trial. The study also revealed greater cutaneous vasoconstriction in both the calf
and thigh during and following cold, as well as cool water immersion trials compared to
the control. The authors concluded that colder water temperature could perhaps be more
effective in treating damage caused by exercise and in rehabilitating injuries due to a
greater reduction in muscle temperature, not muscle blood flow (21).
Wheeler and Jacobson (22) assessed the effects of whole body vibration (WBV) on
delayed onset muscle soreness (DOMS), explosive power, and flexibility following
induced DOMS. The study included 10 men and 10 women, ages 19-23 years, randomly
assigned to either a control or experimental group. Subjects performed baseline
measurements prior to DOMS-induced exercise for explosive power, VAS, hamstring
flexibility, and lower back flexibility. These same variables were measured immediately
following exercise and again immediately following treatment. Following the initial
testing session, the subjects reported back to the lab for four consecutive days at the same
time of day for additional data collection. These sessions included the subjects
participating in a VAS, vertical jump assessment, and a sit and reach. Following the
completion of the assessments, the subjects in the treatment group then spent 10 minutes
on the WBV machines while those in the control group spent 10 minutes walking on a
treadmill. Following the ten minutes of either WBV or treadmill walking VAS, vertical
jump, and the sit and reach assessments were again repeated and recorded.
When comparing pre and post-assessments of explosive power, DOMS, and flexibility
between groups or within groups, no significant difference was found. When comparing
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light exercise to WBV, no significant difference was found for explosive power, DOMS,
or flexibility. The authors concluded that WBV is as equally effective as light exercise as
a treatment modality for lowering the symptoms of DOMS, qualifying it as a recovery
option to be used in addition to other current DOMS treatments (22).
Cantanese (23) sought to determine if skeletal muscle damage, DOMS, as well as
markers of muscle inflammation were affected by external counterpulsation (ECP). Prior
to this study, ECP had been used primarily in treating cardiac patients by compressing the
patient’s lower extremities during diastole increasing coronary perfusion and aiding
venous return. Five males and five females, ages 18-43 years, participated in two 20 mile
runs completed at 70% of their VO2 max, once under a treatment trial and once under a
control trial. Variables measured were lactate dehydrogenase (LDH), C- reactive protein
(CRP), creatine kinase (CK), and perceived leg pain. The variables were measured before
the run, immediately following the run, and daily for five consecutive days on both the
control and treatment conditions. Additionally, in order to control for effects of ECP five
more subjects, ages 24-28 years, remained inactive while receiving five consecutive days
of ECP treatment.
The results indicated no significant changes between the 10 subjects and the control
group receiving ECP treatment only in pain, CRP, CK, and LDH. Subject’s pain, LDH,
and CRP significantly decreased following ECP treatment compared to the control. The
author found that CK remained significantly elevated three days longer in the ECP
treatment group compared to the control. Females experienced a significant difference in
CK and CRP whereas the males did not. In both males and females a 20% reduction in
pain occurred as a result of the ECP treatment, however, females did experience pain for
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one additional day compared to the males. Females also experienced a 20% increase in
LDH compared to the males. The males experienced a significant change in LDH on day
four of the control run, and immediately following the ECP treatment run.
The author concluded ECP treatment decreased inflammation, LDH elevation, and leg
pain in runners following a 20 mile run. When comparing the treatment run to the control
CK levels were found to remain significantly elevated however, it was determined ECP
alone did not cause a significant increase in CK (23).
Effects of Intermittent Pneumatic Compression (IPC) Treatments
Konstantinos and Knaggs (24) examined three intermittent pneumatic compression
(IPC) sequences and their effects on patients with peripheral arterial disease (PAD). The
three IPC sequences examined consisted of separated IPC deliveries to the foot and calf,
and simultaneous compressions on both the foot and calf. These three sequences were
used to determine duration and amplitude decay of acute leg inflow enhancement. The
experimental design was a cross sectional study which included patients with PAD and
intermittent claudication resulting from either superficial femoral artery occlusion or
severe stenosis. The control group consisted of 20 subjects, seven females and 13 males,
ages 44-78 years, with no medical history of cardiovascular disease, claudication, and
with normal circulation. The experimental group consisted of 22 subjects, nine females
and 13 males, ages 50-70 years, diagnosed with intermittent claudication. The
experimental and control groups were matched according to age and gender and were
treated with IPC.
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The baseline volume flow was measured and was determined to be higher in the
experimental group without reaching significance. The peak volume flow measured with
any IPC mode applied was found to be not significantly different between the
experimental and control groups. Additionally, the pulsatility index was found to be
lower in the limbs in the experimental group than in the control. It was also found to be
lower in the experimental group at the baseline level, five seconds after the delivery of
IPC, and throughout the 5 to 50 seconds of its determination with IPC.
Flow enhancement was longer in the simultaneous IPC on the foot and calf versus the
foot only in both the experimental and control groups. Experimental and control group
decay rates of volume flow enhancement indicated a significant decline. Conclusions
drawn from the study indicated that the arteriovenous pressure gradient, nitric oxide, and
peripheral sympathetic auto-regulation are likely to be active following IPC
administration (between 0 and 20 seconds). During the mid-phase (between 20 and 35
seconds) the arteriovenous pressure gradient and peripheral sympathetic auto-regulation
were the only active factors, nitric oxide being excluded. The authors concluded that the
arteriovenous pressure gradient is perhaps the most effective flow enhancer found in the
late phase of flow decay (between 35 and 50 seconds) (24).
Moseley et al. (25) undertook a broad systematic review of common and conservative
therapies to treat secondary arm lymphoedema which included complex physical therapy,
limb exercises and limb elevation, oral pharmaceuticals, manual lymphatic drainage,
compression bandaging and garments, low level laser therapy, and pneumatic pumps. The
study included participants who had a formal diagnosis of chemotherapy-induced and/or,
radiotherapy-induced, secondary arm lymphoedema following breast cancer surgery
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regardless of whether the surgery was a total or partial mastectomy. The study excluded
participants who had primary lymphoedema or recurrent cancer.
Of the studies being reviewed for pneumatic pump therapy, the authors found better
results in volume reduction occurred when the pneumatic pump was combined with other
therapies such as self-massage, manual lymphatic drainage, and compression garments
compared to only using the pneumatic pump as therapy. Additionally, in the reviewed
studies, the pneumatic pump demonstrated the ability to maintain initial volume
reductions in the patients who continued with pneumatic pump therapy (25).
Partsch (26) discussed different therapeutic modalities used in reducing edema and
aiding in venous leg ulcer healing. He emphasized the value intermittent pneumatic
compression (IPC) has in the treatment of limb edema and the associated skin changes
frequently seen on immobile patients’ legs. Partsch discussed how commonplace
compression stockings and compression bandages are not as effective in the treatment of
immobile patients. This is because compression stockings and bandages are not as
efficient in supporting the impaired veno-lymphatic pump but however do impede the leg
from swelling. Comparatively, IPC actively compresses the immobile patient’s limb
producing cyclical pressure waves which mimic the resting and working pressures which
are applied by compression bandages. Partsch further stated that IPC not only reinforced
the veno-lymphatic pump that is critical in restoring damaged microcirculation of the skin
but also reduces limb swelling. Partsch makes the clarion call that using IPC as a
treatment modality is underused, particularly in patients who are immobile and/or bound
to a wheelchair (26).
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Avery et al. (27) presented a case study involving a five month old male diagnosed
with congenital lymphedema in the right lower limb. The five month old patient had been
successfully treated using intermittent pneumatic compression (IPC) therapy. The authors
discussed various treatment options and the pros and cons of each individual treatment in
which IPC is discussed. One of the authors, Dr. Laura Jacobs, defined pneumatic
medicine as using an airtight sleeve made of fabric to apply pressure to an extremity. The
compression device having been calibrated by a physician for both time and pressure is
then used to inflate the fabric sleeve in a rhythmic fashion. Moderate external pressure
compresses the limb and creates a mechanical force which in turn, decongests the tissues
and improves not only lymphatic return but venous return as well.
The authors referenced a study which claimed IPC therapy to be a proven, safe, and an
effective modality in the treatment of lymphedema in patients of all ages (28). In
comparing IPC to complex physical therapy (CPT), there are several advantages in using
IPC over CPT. One advantage being the decongesting of the limb through the sequential
pumping style of distal to proximal compared to the static nature of CPT treatment
methods. The second advantage of using IPC over CPT is the pumping action, duration,
and pressure of the sequential pneumatic compression is both consistent and reproducible
whereas CPT is subject to human inconsistency. The third advantage is IPC treatments
can easily be self-administered on a daily basis and at home whereas CPT requires a
specially trained therapist to administer the therapeutic treatment. The authors cautioned
to rule out deep vein thrombosis by using a duplex ultrasound prior to the initiation lower
limb therapy. The reason being that compression coupled with a deep vein thrombosis
could lead to a pulmonary embolism. The authors concluded that IPC is effective, safe,
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and underutilized in reducing and treating children diagnosed with congenital
lymphedema (27).
Labropoulos et al. (29) sought to determine if the use of intermittent pneumatic
compression (IPC) in patients with critical limb ischemia would increase skin,
gastrocnemial, collateral arterial, and popliteal blood flow. All patients included in the
study had at least two-level disease diagnosed by angiography. The average age of the
study participants was 74 years. Using laser Doppler fluxmetry and duplex ultrasound
scans, 20 limbs which had been diagnosed with critical limb ischemia in 20 patients were
assessed in a semi-erect position before, during, and following IPC treatments. Of the 20
limbs, 14 of the limbs had been identified as inoperable, and six had been identified as
marginal for reconstruction. One pneumatic cuff was placed on the foot and the second
on the calf using a maximum inflation pressure of 120 mmHg with the compression cycle
set at three seconds with three cycles per minute. The flow volumes measured in the
study consisted of the popliteal, genicular collateral artery and the medial gastrocnemial
with the skin blood flow being measured at the same time on the dorsum of the foot.
The results indicated a significant increase in the flow of all three arteries compared to
baseline levels with the highest change found in the popliteal, with the gastrocnemial and
the collateral artery following suit respectively. Following the discontinuance of the IPC,
blood flow returned to baseline values which can be attributed to the diameter of the
arteries not changing. The increase in skin blood flow was also significant. The results
also indicated of the 20 limbs measured there were two which did not increase in arterial
or in skin blood flow. This was attributed to a significant popliteal vein reflux and both of
the two limbs were amputated not long after the completion of the study. The authors
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concluded that IPC augments skin, muscular, axial, and collateral blood flow in patients
diagnosed with critical limb ischemia. However, patients with significant venous reflux
may not benefit from using IPC. The authors further concluded that IPC may prove
beneficial for patients who may not be candidates for revascularization and that IPC
enhances blood flow through augmenting the arterio-venous pressure gradient (29).
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CHAPTER III
METHODS
An experimental design was used to test the effectiveness of the NT recovery unit. The
independent variable was the NT recovery treatment vs. the control condition. The
dependent variables were the biochemical marker associated with inflammation; CRP;
and DOMS. The study was delimited to trained long distance runners capable of running
20 miles at 70% or above of their maximum heart rate.
Subjects
Ten subjects, five trained males and five trained females, age 20 to 53 years, who
attended Cleveland State University (CSU) or lived in the surrounding Cleveland, OH
area were enrolled. The subjects were obtained through a convenience sample, by
recruiting volunteers from local running and triathlon clubs, and individuals from the
CSU women’s cross country team. The subjects consisted of marathoners, ultra
marathoners, ironman triathletes, and collegiate athletes. All potential subjects completed
an AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire (30,
Appendix B) to measure potential health risk factors for people engaging in an exercise
program. Subjects needed to be in the “Low Risk” category after completing the
screening questionnaire. Subjects included in the study were trained and capable of
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running 20 miles at 70% of their VO2 max. Subjects were excluded from participating in
the study if they had a history of musculoskeletal, cardiovascular, circulatory, or any
other health problems which may have put them at risk if they participated in the study.
All subjects were asked to refrain from other physical activity, flu shots or other
immunizations, and other recovery treatments such as stretching, ice baths, or consuming
anti-inflammatory medications such as NSAIDS during the six days they participated in
the study, as well as 48 hours before the start of the six days. Subjects were also not
permitted to participate in the study if they had a cold, and had to wait until they had
completely recovered from their cold as inflammation levels would not be a valid
indicator of exercise inflammation.
Procedures
Subjects who qualified to participate in the study signed an informed consent form
(Appendix C) approved by the Institutional Review Board at CSU (Appendix D).
Subjects who qualified for the study were required to perform a graded VO2 max test to
establish running intensity (70 % VO2 max) for the running trial. A cross-over design was
implemented and subjects were randomly assigned to either the treatment run or the
control run for their first 20 mile run to avoid order effect. The second run was completed
three to four weeks after completing the first run. Test participants were asked to refrain
from training 48 hours prior to their 20 mile run. Procedures for this study were based on
a previous study conducted in the human performance lab at CSU (23).
Immediately before each participant started their 20 mile run, baseline data was
collected. Nude weights were taken immediately before and after the run using a
physician’s beam scale, and height using a stadiometer. CRP blood samples were
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obtained via venipuncture using SST BD Vacutainer serum collection tubes (3.5 mL).
Blood samples sat for 30 minutes to coagulate then were spun down using a centrifuge at
2900 RPM for 10 minutes.
Once the baseline measurements were acquired, the run started on a premeasured
course. The test subjects completed a 20 mile run at an intensity of 70% or higher of their
VO2 max. Each runner wore a Polar heart rate monitor to monitor the running intensity
(heart rate corresponding to 70% VO2 max obtained during the max test). Subjects were
provided water, or their preferred liquid, to drink during competition or training,
according to each participant’s specific hydration routine to prevent dehydration. Fluid
intake was monitored and recorded for each runner. Immediately after the 20 mile run,
another venous blood sample was taken from the anticubital vein for CRP. Perceived pain
was assessed using the Management of Cancer Pain Scale Test (31, Appendix E); body
weight was again obtained to determine fluid loss from dehydration and to calculate
sweat rate. Subjects who completed the treatment run received treatment using the NT
recovery system immediately following blood sampling.
All treatment subjects received the same treatment, one hour of NT at an intensity
setting of 10 (90mmHg for cell 1 and cell 5 and100 mmHg for cells 2-4) with a
compression duration of 30 seconds. The NT recovery system is a boot which is divided
into five sections and in each of these five sections there are inflatable bladders or cells.
Cell one is located on the foot and each cell continues up the leg to the top of the thigh
where cell five is located. Each bladder or cell inflates or compresses the limb for 30
seconds. NT recommends that for athletes, the intensity setting be at 10 (intensity settings
range from 1-10) to ensure the best results for recovery. The amount of pressure exerted
on the limb at an intensity setting of 10 in each of the cells is as follows: cell one and cell
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five - 90mmHg; cells two, three, and four - 100mmHg. This inflation is synchronized to
mimic a massaging action and to increase blood flow. Each leg was treated
simultaneously.
For five consecutive days after the run, blood samples were obtained for CRP.
Perceived pain was recorded and subjects used the NT device for five consecutive days.
Subjects who did not receive treatment after the 20 mile run will underwent the same
protocol except for the NT treatment, and were able to leave the lab after CRP and pain
were measured.
The second 20 mile run was held approximately three to four weeks after the first 20
mile run to ensure complete recovery. Subjects who were previously in the treatment trial
participated in the control trial, while those who were previously in the control trial
participated in the treatment trial. Procedures for the second 20 mile run were exactly the
same as those in the first 20 mile run.
Data Analysis
Descriptive statistics were acquired on all measures. A repeated measures ANOVA
was used to assess recovery within a treatment group, whereas a two-way ANOVA was
used to assess treatment differences due to NT recovery treatment vs. control on CRP and
subjective pain across the five days. SPSS (version 18) was used for all analyses with
0.05 used as the level of significance. Paired sample t-tests were used to specify
differences across the five days.
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CHAPTER IV
RESULTS & DISCUSSION
Results
Ten subjects, five males and five females participated in the study to determine the
effectiveness of the NT compression system for recovery after a 20 mile run. As
expected, the males were taller, heavier, and had a higher VO2 max than the female
runners (Table 1).
Table 1. Characteristics of the subjects.
Characteristics
Age (years)
Height (cm)
Weight (kg)
VO2 Max (ml·min·kg)

Males (N=5)
Mean ± SD
41.2 ± 10.6
176.7 ± 4.5
74.1 ± 4.5
54.1 ± 4.5

Females (N=5)
Mean ± SD
36.2 ± 12.4
164.6 ± 5.2
60.5 ± 5.2
48.6 ± 6.0

Total Group (N=10)
Mean ± SD
38.7 ± 11.2
170.7 ± 7.8
67.3 ± 8.5
51.4 ± 5.8

Males were found to be significantly taller and weigh significantly more than the
female runners. No significant difference was found in age or VO2 max between genders
(Table 2).
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Table 2. Gender comparison of age, height, weight, and VO2 max of the subjects.
Condition (N=10)
Male vs. Female Age
Male vs. Female Height
Male vs. Female Weight
Male vs. Female VO2 Max
* Indicates significance

Mean ± SD
41.2 ± 10.6 vs. 36.2 ± 12.4
176.7 ± 4.5 vs. 164.6 ± 5.2
74.1 ± 4.5 vs. 60.5 ± 5.2
54.1 ± 4.5 vs. 48.6 ± 6.0

P - value
.608
.046*
.013*
.254

There was no significant difference in mean weight loss, fluid intake, sweat rate, heart
rate, percentage of maximum heart rate, or percentage of maximum VO2 max between
runs (Table 3). There was, however, a significant difference (P = .038) in running time
when comparing the control run against the treatment run. This was likely due to
differences in weather conditions.
Table 3. Comparison between the control run and the NT treatment run.
Condition (N=10)
Weight Loss (kg)

Control (Mean ± SD)
1.17 ± .74

Treatment (Mean ± SD)
1.32 ± .72

P - value
.370

Fluid Intake (ml)

1087.3 ± 505.7

1307.8 ± 728.2

.308

Sweat Rate (L/hr)

.37 ± .28

.40 ± .23

.649

Heart Rate (bpm)

143.9 ± 10.8

147.8 ± 12.8

.213

% Max Heart Rate (bpm)

79.8 ± 6.5

81.8 ± 5.6

.222

% VO2 Max (ml/min/kg)**

72.3 ± 9.0

69.8 ± 10.9

.082

Running Time (min)

196.2 ± 28.7

204.8 ± 31.1

.038*

* Indicates significance
** Estimated from American College of Sports Medicine (ACSM) formula
To determine if the first run had an effect on the second run, a repeated measures
ANOVA was used comparing all of the first runs with all of the second runs. The results
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indicated no significant difference (P > 0.05) in any variables except for in one of the pain
ratings. When comparing the pain experienced immediately following the first run versus
second run, runners indicated they experienced more pain following the second run (4.9
on VAS) compared to the first run (3.7 on VAS). This slight increase in pain on the
second run occurred regardless of whether the run was a treatment run or a control run.
CRP
No significant difference between the control run and the treatment run was found for
CRP (Table 4). The subjects recovered by day four while using the NT device whereas
the control had still not recovered by day five. However, this difference was not
significant.
Table 4. Comparing baseline CRP values to post run CRP values.
Condition (N=10)
Control Post Run
Control Day 1
Control Day 2
Control Day 3
Control Day 4
Control Day 5
Normal = 2.9 mg/L

Mean ± SD
2.90 ± 0.00
7.06 ± 3.39
5.92 ± 4.20
4.80 ± 4.90
3.68 ± 2.33
3.17 ± 0.85

P - value
---.004*
.049*
.251
.317
.343

Condition (N=10)
Treatment Post Run
Treatment Day 1
Treatment Day 2
Treatment Day 3
Treatment Day 4
Treatment Day 5

Mean ± SD
2.90 ± 0.00
7.95 ± 4.08
4.85 ± 1.95
3.19 ± 0.72
2.94 ± 0.13
2.90 ± 0.00

P - value
---.004*
.012*
.234
.343
----

* Indicates significant difference from baseline
The results indicated no significant difference in CRP levels between the control run
and treatment run. However, the subjects recovered one day earlier when using the NT
device compared to the control. Statistically this may not be significant, but a full day
recovery for a professional athlete is important (Figure 2).
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Figure 2. Control Run vs Treatment Run.
CRP Gender Comparisons
When the males used the NT device, there were significant increases in CRP from
baseline on days one and two. The results indicated the males had recovered by day three,
compared to the control, who had still not recovered by day five (Table 5). However, this
difference was not significant.
Table 5. Comparing male baseline CRP values to each recovery day.
Condition (N=5) Mean ± SD
Control Post Run 2.90 ± 0.00
Control Day 1
7.00 ± 3.72
Control Day 2
6.98 ± 5.60
Control Day 3
6.32 ± 6.90
Control Day 4
4.38 ± 3.31
Control Day 5
3.44 ± 1.21
Normal = 2.9 mg/L

P - value
---.069
.178
.329
.374
.374

* Indicates significant difference from baseline
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Condition (N=5)
Treatment Post Run
Treatment Day 1
Treatment Day 2
Treatment Day 3
Treatment Day 4
Treatment Day 5

Mean ± SD
2.90 ± 0.00
7.76 ± 3.53
4.42 ± 1.11
2.94 ± 0.09
2.90 ± 0.00
2.90 ± 0.00

P -value
---.037*
.038*
.374
-------

No significant difference was determined from baseline in either the control run or the
treatment run among the female runners. Additionally, the females recovered in the same
amount of time (by day four) regardless if they were using the NT device (Table 6).
Table 6. Comparing female baseline CRP values to each recovery day.
Condition (N=5) Mean ± SD
Control Post Run 2.90 ± 0.00
Control Day 1
7.12 ± 3.48
Control Day 2
4.86 ± 2.37
Control Day 3
3.28 ± 0.85
Control Day 4
2.98 ± 0.18
Control Day 5
2.90 ± 0.00
Normal = 2.9 mg/L

P - value
---.053
.138
.374
.374
----

Condition (N=5)
Treatment Post Run
Treatment Day 1
Treatment Day 2
Treatment Day 3
Treatment Day 4
Treatment Day 5

Mean ± SD
2.90 ± 0.00
8.14 ± 4.99
5.28 ± 2.62
3.44 ± 1.00
2.98 ± 0.18
2.90 ± 0.00

P -value
---.078
.112
.293
.374
----

* Indicates significant difference from baseline
Pain
A significant difference from the baseline pain rating occurred from the time of the
post run until day three for both the control run and treatment run. During the treatment
run trial however, the test subjects had no pain on day five while using the NT device
compared to the control in which the subjects still had some pain on day five (Table 7).
Table 7. Comparing baseline pain ratings to post run pain ratings.
Condition (N=10) Mean ± SD P - value
Control Post Run
4.10 ± 2.42 .000*
Control Day 1
2.90 ± 1.51 .000*
Control Day 2
2.35 ± 1.38 .000*
Control Day 3
0.95 ± 1.26 .041*
Control Day 4
0.40 ± 0.84 .168
Control Day 5
0.10 ± 0.32 .343
Scale 0 (no pain) - 10 (worst pain possible)

Condition (N=10)
Treatment Post Run
Treatment Day 1
Treatment Day 2
Treatment Day 3
Treatment Day 4
Treatment Day 5

* Indicates significant difference from baseline (no pain)
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Mean ± SD
4.70 ± 1.42
3.00 ± 1.76
2.15 ± 1.86
1.00 ± 1.05
0.20 ± 0.48
0.00 ± 0.00

P -value
.000*
.000*
.005*
.015*
.223
----

Pain Gender Comparisons
In males, the pain ratings during the control trial were significantly elevated from
baseline until day three while the treatment trial ratings were only significantly elevated
until day one. This indicates that the males had significant pain through day two on the
control run compared to significant pain only through day one on the treatment run when
using the NT device (Table 8).
Table 8. Comparing male baseline pain ratings to post run pain ratings.
Condition (N=5) Mean ± SD
P - value
Control Post Run 3.60 ± 2.88
.049*
Control Day 1
3.30 ± 1.92
.019*
Control Day 2
2.50 ± 2.00
.049*
Control Day 3
1.10 ± 1.67
.216
Control Day 4
0.40 ± 0.89
.374
Control Day 5
0.00 ± 0.00
---Scale 0 (no pain) - 10 (worst pain possible)

Condition (N=5)
Treatment Post Run
Treatment Day 1
Treatment Day 2
Treatment Day 3
Treatment Day 4
Treatment Day 5

Mean ± SD
4.40 ± 1.82
2.60 ± 1.95
2.10 ± 2.25
1.00 ± 1.41
0.30 ± 0.67
0.00 ± 0.00

P -value
.006*
.041*
.105
.189
.374
----

* Indicates significant difference from baseline (no pain)
The female pain ratings indicated significantly elevated pain ratings from baseline in
the treatment trial until day three compared to the control trial where pain ratings were
only significantly elevated from baseline until day two. This indicates that the females
had higher amounts of pain while using the NT device (Table 9).
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Table 9. Comparing female baseline pain ratings to post run pain ratings.
Condition (N=5) Mean ± SD
P - value
Control Post Run 4.60 ± 2.07
.008*
Control Day 1
2.50 ± 1.00
.005*
Control Day 2
2.20 ± 0.45
.000*
Control Day 3
0.80 ± 0.84
.099
Control Day 4
0.40 ± 0.89
.374
Control Day 5
0.20 ± 0.45
.374
Scale 0 (no pain) - 10 (worst pain possible)

Condition (N=5)
Treatment Post Run
Treatment Day 1
Treatment Day 2
Treatment Day 3
Treatment Day 4
Treatment Day 5

Mean ± SD
5.00 ± 1.00
3.40 ± 1.67
2.20 ± 1.64
1.00 ± 0.71
0.10 ± 0.22
0.00 ± 0.00

P -value
.000*
.010*
.040*
.034*
.374
----

* Indicates significant difference from baseline (no pain)
Temperature Conditions During the 20 Mile Runs
The temperature of the first run was compared to the temperature of the second run to
determine if a difference occurred. There was a significant difference (P = .030) between
the temperatures of the first run (6.4 ºC) compared to the second run (2.8 ºC). The
temperature of the control run (4.8 ºC) was compared to the temperature of the treatment
run (4.4 ºC) to determine if a difference occurred. No significant difference (P = .855)
was found in temperature between the control and treatment runs.
Discussion
C- reactive protein levels peaked on Day 1 for both the control and treatment runs and
then gradually decreased until they returned to baseline by day 4 (NT) and day 5
(control). This is consistent with the research performed by Fallon (32) who stated that
the acute phase response has been suggested to relate to skeletal muscle damage when
associated with exercise. The acute phase response is a response of certain proteins in the
blood plasma whose concentrations either increase or decrease due to inflammation. Creactive protein is reported to be the most plentiful of the acute phase proteins and has
been reported to be elevated following exercise, especially when muscle damage has
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occurred (32, 33). C- reactive protein remained higher than baseline until Day 5 for the
control run but remained higher than baseline only until day 4 for the treatment run.
These results are consistent with the literature (32, 33).
A study performed by Milias et al. (5) found no significant differences in the
inflammatory markers CRP, complement C3, and fibrinogen following eccentric exercise.
Simpson et al. (34) also found no significant difference in CRP even after a hill race
although muscle damage was present. This suggests that inflammation may not
correspond to muscle damage. The results of the present study support this.
The results in the present study conflict with those found in a previous study by
Cantanese (23) in which the same experimental protocol was used, except external
counter pulsation (ECP) was the treatment modality. In that study, ECP helped the
runners recover two days faster than in the control trial which was statistically significant.
Additionally, only the females in the ECP study experienced a significant difference in
CRP whereas in the current study, it was the males who responded to the treatment. The
major differences between treating the runners with ECP compared to NT were the cuff
pressure and compression duration. The maximum ECP cuff pressure was 6 psi and the
maximum NT cuff pressure was 2.1 psi. The ECP compression duration only lasted
during diastole (about a second) whereas the NT compression lasted about one minute.
The difference in cuff pressure and compression may have contributed to why we did not
obtain the same results with the NT device as Cantanese (23) did with the ECP study.
When comparing the first run against the second run for both males and females, CRP
peaked on day one for both runs but the peak on the second run was 1.4 mg/L less than
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the peak on the first run. This is also consistent among gender with the second run 1.7
mg/L less CRP among males and 1.0 mg/L less CRP among females compared to the first
run, suggesting rapid adaptation. In a study by Clarkson et al. (35), less muscle damage
was produced when the same exercise was performed several months later due to
adaptation. Rapid adaptation could potentially explain smaller responses seen after
downhill running due to preadaptation. The exact etiology of this adaptation is not
known. In the study by Clarkson et al. (35), one group exercised six weeks apart and after
the second bout of exercise DOMS, and flexed arm angle responses were found to be
significantly smaller. This may explain the blunted peak CRP response on the second run
for both males and females, and suggests a longer span of time needed between the
treatment and control runs (six weeks or longer) to mitigate long-term adaptations.
Concerning gender, the males recovered about two days faster using the NT device
compared to control but the females did not recover faster using the NT device compared
to control. When comparing the male CRP values to baseline, the males had a significant
difference from baseline on day one and two when using NT compared to the control (no
significant difference from baseline) suggesting NT made the inflammation worse. The
CRP values compared to baseline among females revealed no significant difference from
baseline suggesting there was no benefit in using NT. Regarding gender differences, there
has been some debate as to the existence of sex differences in exercise-induced muscle
damage and repair based on an assumption that estrogen levels exert a response that may
enhance the recovery of skeletal muscle to damaging exercise. These assumptions are
based on estrogen’s potential ability to stabilize the cells of skeletal muscle during
exercise due to estrogen’s antioxidant properties (36). Studies that assess DOMS or pain
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usually do not find sex differences (37, 38, 39) and those that do site differences between
men and women are inconsistent (36). Another study demonstrated that there were no
differences in sex when comparing untrained men and women in muscle fatigue or other
changes in muscle function parameters during eccentric exercise (40). The results from
the present study, however, indicate a difference in gender response to the NT recovery
device adding to the inconsistency of whether gender differences exist.
Previous physical conditioning is the most effective technique to speed up the
recovery process after strenuous exercise (41). The majority of subjects involved in the
study were trained marathoners, ultramarathoners, triathletes, and collegiate athletes. Two
subjects (one male and one female) did not elicit a CRP response following the protocol
on either the control run or treatment run. The level of training (perhaps due to interval
training) and running efficiency of the subjects may possibly have contributed to the lack
of an inflammatory response, limiting the effectiveness of the NT recovery device, which
could influence the results of the study.
Pain
When comparing pain ratings to baseline, the results indicated no significant
difference between NT and control. The male pain ratings were significant from baseline
until day one in the treatment trial compared to the control which was significant from
baseline until day two, indicating NT helped ease the pain one day sooner for the males.
The females exhibited the opposite. The female pain ratings were significant from
baseline until day two in the control trial compared to the treatment which was significant
from baseline until day three, indicating the females had more pain while using NT.
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Perceived pain in all 10 subjects while using the NT device was lower compared to the
control. This is consistent with a study by Hilbert et al. (42) in which they tested the
physiological and psychological effects of massage on DOMS. They concluded massage
may provide psychological benefits as it reduces the intensity of soreness which is
commonly associated with DOMS (42). Many subjects, both male and female, stated that
while using the NT device they kept waiting for the pain associated with DOMS to come
a day or two after the run and they stated it never came. These statements are subjective
and based on self-reported data.
When comparing the first run to the second run for pain there was a significant
difference between the two runs. The subjects in the second run experienced less pain
compared to the first run. However, when comparing the first run to the second run in
terms of gender, no significant difference was found. For males, by day two the second
run recorded lower pain levels compared to the first run while the females recorded a
higher level of pain in the second run compared to the first run.
Temperature
Temperature and weather may have played a role in the present study. Testing started
on October 21, 2013 and ended January 18, 2014. Subjects started the study in ideal
running conditions but as the study progressed subjects ran in cooler conditions. A
significant difference between the temperatures of the first run compared to the second
run was found. This may suggest why the second run was significantly slower compared
to the first in Table 3. No significant difference was found in temperature between the
control and treatment runs.
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CHAPTER V
SUMMARY & CONCLUSION
Ten trained runners ran two 20 mile runs and each subject participated in the control
and treatment runs. Trails were randomly counterbalanced to provide a safeguard against
order effect. Muscle soreness was induced on both runs to elicit a CRP response and
subjects were asked to rate their pain immediately following the run and each day after
for five days.
The subjects recovered by day four while using the NT device whereas the control had
still not recovered by day five. However, this difference was not significant. The results
indicated the males had recovered by day three, compared to the control, who had still not
recovered by day five. However, this difference was not significant. No significant
difference was determined from baseline in either the control run or the treatment run
among the female runners and the females recovered in the same amount of time (by day
four) regardless if they were using the NT device.
During the treatment run trial, the test subjects had no pain on day five while using the
NT device compared to the control in which the subjects still had some pain on day five.
The males had significant pain through day two on the control run compared to
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significant pain only through day one on the treatment run when using the NT device.
The female pain ratings indicated significantly elevated pain ratings from baseline in the
treatment trial until day three compared to the control trial where pain ratings were only
significantly elevated from baseline until day two, indicating that the females had higher
amounts of pain while using the NT device.
In conclusion, the results indicated statistically there was no significant difference in
CRP or pain levels between the control run and treatment run therefore, my hypothesis
was rejected. However upon closer inspection, the data suggests the test subjects
recovered one day earlier when using the NT device compared to the control. Statistically
this may not be significant, but a full day recovery for a professional athlete is very
important. Gender differences were found in response to the control and treatment run. It
appears based on the present study that males respond better to being treated with NT
compared to the females in reducing inflammation following a 20 mile run.
Application
There are many devices used to help athletes recover faster. Unfortunately, many of
them do not work as advertised, and many have not undergone sufficient scientific
research to support or reject their claims. Coaches, athletic trainers, and athletes should
seek scientific support of therapeutic interventions which claim to help reduce the effects
of muscle damage, DOMS, and speed of recovery from exercise and athletic endeavors.
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Limitations
Limitations of the study were identified as follows:
1. Running weather conditions varied. Warmer and cooler temperatures can
influence cardiac drift and level of hydration which can affect heart rate, exercise
performance, and DOMS (thereby affecting the release of biochemical markers of
muscle damage).
2. The sample was one of convenience and was small (N=10), requiring caution
when making extrapolations from the results to larger populations.
3. Variables which could affect enzyme activity such as training level, muscle fiber
composition, past injuries, and the degree of hormonal activity, were not
controlled.
4. In the study performed by Cantanese (30), sensitivity of CRP was to 1 mg/L. We
outsourced the measurement of CRP to a local hospital where CRP was only
sensitive to 2.9 mg/L. Clinically, any measurement of CRP of 2.9 mg/L or less is
acceptable. However, lower CRP values could have a significant impact on the
outcome of the study.
Future Research Recommendations
1. Future research is needed with a larger sample size.
2. Future research examining a different population such as sedentary, untrained, or
elderly populations is needed to determine if the NT device would function better
with untrained individuals.
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3. Future research including other markers of muscle damage and inflammation such
as CK, LDH, and Mb is needed to obtain a clearer picture of the mechanism and
to determine if there is a relationship between the biochemical markers.
4. Future research is needed that focuses on other types of exercise, besides long
distance running, which may also cause muscle damage.
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AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire
Assess your health needs by marking all true statements.
History
You have had:
___ A heart attack
___ Heart surgery
___ Cardiac catheterization
___ Coronary angioplasty (PTCA)
___ Pacemaker/implantable cardiac defibrillator/rhythm disturbance
___ Heart valve disease
___Heart Failure
___ Heart transplantation
___ Congenital heart disease
Symptoms
___ You experience chest discomfort with exertion.

If you marked any of these statements in this section, we
require a physician’s release, attached, in order to continue
with the joining process.

___ You experience unreasonable breathlessness.
___ You experience dizziness, fainting, blackouts.
___ You take heart medications.
Other health issues
___ You have diabetes
___ You have or asthma other lung disease.
___ You have burning or cramping in your lower legs
when walking short distances.
___ You have musculoskeletal problems that limit your physical activity
—– You have concerns about the safety of exercise.
—-- You take prescription medication(s)
—-- You are pregnant
__________________________________________________________________________________________________________
Cardiovascular risk factors
___ You are a man older than 45 years.
___ You are a woman older than 55 years, you
have had a hysterectomy, or you are postmenopausal.
___ You smoke, or quite within the previous 6 mo.
___ Your blood pressure is greater than 140/90.

If you marked two or more of the statements in this section
you are required to obtain a physician’s release, attached, in
order to join the facility.

___ You don't know your blood pressure.
___ You take blood pressure medication.
___ Your blood cholesterol level is >200 mg/dL.
___ You don't know your cholesterol level.

___ You have a close blood relative who had a heart attack before age 55 (father or brother) or age
65 (mother or sister).
___ You are physically inactive (i.e., you get less than 30 min. of physical activity on at least 3
days per week).
___ You are more than 20 pounds overweight
______________________________________________________________________________________
___ None of the above is true.
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You should be able to exercise safely without consulting
your physician or other healthcare provider in a self-guided
program or almost any facility that meets your exercise
program needs.
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INFORMED CONSENT FOR PARTICIPATION
Effects of Intermittent Pneumatic Compression on Delayed Onset Muscle Soreness
in Long Distance Runners

Introduction
You have been asked to participate in a research study to be conducted in the Human
Performance Laboratory at Cleveland State University. The purpose of this study is to
measure the recovery process from prolonged distance running with the use of NormaTec
Recovery system and its effect on reducing delayed onset muscle soreness (DOMS).
Previous studies have documented the delayed onset of muscle soreness is an effect of
performing an exercise which places a great deal of strain on the skeletal muscles. The
subsequent strain that is placed on the muscles leads to the release of biochemical
markers into the blood. These biochemical markers indicate damage has been done to the
muscle and can lead to muscle soreness. One of these biochemical markers is lactate
dehydrogenase (LDH). Inflammation is the precursor to full recovery of damaged muscle
fibers. Inflammation is indicated by another blood marker called C- reactive protein
(CRP). C- reactive protein indicates the healing process is underway. NormaTec is a
company which has developed a device used by athletes to help them recover faster. It
utilizes intermittent pneumatic compression cuffs to inflate, hold, and deflate different
areas of the leg aiding in blood flow, profusion, and return back to the heart (similar to
message).

Procedures
I understand that I will be asked to perform a maximal graded exercise test to establish
run intensity. I understand a continuous measurement of oxygen consumption will be
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recorded throughout the test. Oxygen consumption will be measured using the Cosmed
K4 b2 portable oxygen analyzer. I understand that this test involves running at
comfortable training pace with the treadmill elevating 3% every three minutes until I
reach a maximal grade in which I cannot continue the run. I understand that this test takes
approximately 10-15 minutes and is dependent on my conditioning. Values usually range
for someone of my ability between 45 and 60 milliliters of oxygen per kilogram of body
weight each minute. I know that I can voluntarily stop exercise if I experience any
problems.
We ask that you do not do any hard training 48 hours prior to the initial testing. After the
initial testing you will report to the Human Performance laboratory where baseline data
will be obtained prior to your long run, this involves a venous blood sample, height, and
weight. You will then be instructed to complete a 20 mile run at approximately 70 % of
your maximal heart rate (moderate intensity). Blood samples will be drawn immediately
after the run and each day after until baseline measures are again achieved.
You will complete the same run twice. After one of the runs you will be treated with
NormaTec recovery system (60 minute duration) daily until blood markers return to
normal. The second run will be the control where only the blood markers will be
measured and no NormaTec treatment will be given. During the days after your long run
we ask that you refrain from training while recovery is being evaluated.

Risks and Discomforts
I understand that during maximal exercise testing, there exists the possibility of certain
changes occurring; these include abnormal blood pressure, fainting, disorders of the heart
rhythm, and rare instances of heart attack, stroke or death (1:20,000 exercise tests). I
understand the laboratory has emergency procedures in place and every effort will be
made to minimize these risks. The laboratory is equipped with an AED and all lab
personnel are trained in CPR and First Aid. Emergency procedures including calling
EMS (x911) stating to the dispatcher:” We have a medical emergency in the Human
Performance Laboratory PE Building- Room B60”. CPR/First aid will be administered
until EMS arrives. Emergency procedures are posted throughout the laboratory. I also
know that I can voluntarily stop exercise if I experience any problems
I understand other risks associated with this study include muscle soreness resulting from
the 20 mile run. Discomfort will also be experienced from giving venous blood samples.
The risk associated with the run would be the same experienced from your normal
training regimen. Every effort will be made to minimize these risks. A registered nurse
will perform all the blood samples drawn and a qualified technician will be responsible
for administering the NormaTec treatment.
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Benefits
The benefits of the study are significant because it will help further our understanding of
therapeutic interventions to help reduce the effects of muscle damage, DOMS and speed
of recovery from exercise and athletic endeavors. The results of this study could be
applied to professional and non-professional athletes who spend a great deal of time
training, especially those who perform long duration eccentric exercises. The NormaTec
treatment system can aid in decreasing recovery time so that training can continue sooner.

Confidentiality
To protect your privacy, your name will not be used in any document of the project. The
information, however, may be used for a statistical or scientific purpose with your right of
privacy retained.

Participation
I understand that participation in this project is voluntary and that I have the right to
withdraw at any time with no consequences. I understand that if I have any questions
about my rights as a participant, I can contact Cleveland State University’s Review Board
at (216) 687-3630, and if I have any questions about the procedures I can contact Dr.
Kenneth Sparks at (216) 687-4831 or Mr. Shane Draper at (440) 313-2909. I also
understand that I will be compensated ($200) for my time.
I attest and verify that I have no known health problems that could prevent me from
successfully participating in the sub-maximal graded exercise test.

Patient Acknowledgement
The procedure, purposes, known discomforts and risks, possible benefits to me and to
others have been explained to me. I have read the consent form or it has been read to me,
and I understand it.
I agree to participate in this program. I have been given a copy of this consent form.
Signature: ________________________________________

Date: ____________

Witness: __________________________________________

Date: ____________
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Cleveland
State
University
engaged/earning

Memorandum
Institutional Review Board

To:

Kenneth Sparks
HPERD, PE 860

From:

Craig M. Zullig
Director
Office of Sponsored Programs & Research

Date:

August 26, 2013

Re:

Results of IRB Review of your project number: #29876-SPA-HS
Co-Investigator: Shane Draper, Student

Title: Effects of Intermittent Pneumatic Compression on Delayed Onset Muscle
Soreness (DOMS) in Long Distance Runners
The IRB has reviewed and approved your application for the above named project, under the
category noted below. Approval for use of human subjects in this research is for a one-year period
as noted below. If your study extends beyond this approval period, you must contact this office to
initiate an annual review of this research.
By accepting this decision, you agree to notify the IRB of: (1) any additions to or changes in
procedures for your study that modify the subjects' risk in any way; and (2) any events that affect that
safety or well-being of subjects. Notify the IRB of any revisions to the protocol, including the addition
of researchers, prior to implementation.
Thank you for your efforts to maintain compliance with the federal regulations for the protection of
human subjects.

Approval Category:
Expedited (7)

Approval Date:

August 26, 2013

Expiration Date:

August 25, 2014
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